APA (7th ed.) Citation

C, X., B, M., J, Q., G, Q., H, Y., H, W., . . . Y, L. (2022). NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models. Translational oncology, 16, 101322. https://doi.org/10.1016/j.tranon.2021.101322

Chicago Style (17th ed.) Citation

C, Xu, Marelli B, Qi J, Qin G, Yu H, Wang H, Jenkins MH, Lo KM, and Lan Y. "NHS-IL12 and Bintrafusp Alfa Combination Therapy Enhances Antitumor Activity in Preclinical Cancer Models." Translational Oncology 16 (2022): 101322. https://doi.org/10.1016/j.tranon.2021.101322.

MLA (9th ed.) Citation

C, Xu, et al. "NHS-IL12 and Bintrafusp Alfa Combination Therapy Enhances Antitumor Activity in Preclinical Cancer Models." Translational Oncology, vol. 16, 2022, p. 101322, https://doi.org/10.1016/j.tranon.2021.101322.